A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs D 0502 (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors InventisBio
- 05 Aug 2019 Planned End Date changed from 1 Oct 2020 to 1 Oct 2021.
- 05 Aug 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.
- 20 Jun 2018 Status changed from not yet recruiting to recruiting.